Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder

Journal of Clinical Psychopharmacology

Volumn 28, Issue 3 SUPPL. 2, 2008, Pages

  Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NORADRENALIN;

ATTENTION DEFICIT DISORDER; CHILD; CORPUS STRIATUM; DRUG EFFECT; HUMAN; METABOLISM; NERVE CELL NETWORK; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; METHYLPHENIDATE; NERVE NET; NOREPINEPHRINE; PREFRONTAL CORTEX; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 52049086956     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318173312f     Document Type: Review

References (77)

1. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191-222.
2. Wilens TE, Spencer TJ. The stimulants revisited. Child Adolesc Psychiatr Clin N Am. 2000;9(3):573-603, viii. (Pubitemid 30620545)
3. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030. (Pubitemid 30112216)
4. Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc Psychiatry. 2000;9(suppl 1):I27-I43.
5. Novartis Pharmaceuticals Corp. Focalin [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corp; 2001.
6. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl):26S-49S.
7. Swanson JM, Gupta S, Williams L, et al. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry. 2002;41:1306-1314. (Pubitemid 38338021)
8. Erratum in: J Am Acad Child Adolesc Psychiatry. 2003;42:260.
9. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:24-29. (Pubitemid 38134162)
10. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d, l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1406-1414. (Pubitemid 39411041)
11. Arnold LE, Lindsay RL, Conners CK, et al. A double-blind, placebocontrolled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2004;14:542-554.
12. Boonstra AM, Kooji JJ, Oosterlaan J, et al. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhoodonset ADHD? J Clin Exp Neuropsychol. 2005;27:278-298. (Pubitemid 40523416)
13. Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am. 2001;85:757-777. (Pubitemid 32397225)
14. Okie S. ADHD in adults. N Engl J Med. 2006;354:2637-2641.
15. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.
16. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118:1215-1219. (Pubitemid 46090066)
17. Crawford CA, McDougall SA, Meier TL, et al. Repeated methylphenidate treatment induces behavioral sensitization and decreases protein kinase A and dopamine-stimulated adenylyl cyclase activity in the dorsal striatum. Psychopharmacology (Berl). 1998;136:34-43. (Pubitemid 28097518)
18. Vaidya CJ, Austin G, Kirkorian G, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A. 1998;95:14494-14499. (Pubitemid 28549395)
19. Grillner S, Hellgren J, Menard A, et al. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci. 2005;28:364-370. (Pubitemid 40853859)
20. Monchi O, Petrides M, Strafella AP, et al. Functional role of the basal ganglia in the planning and execution of actions. Ann Neurol. 2006;59:257-264. (Pubitemid 43202478)
21. Moll GH, Heinrich H, Trott G, et al. Deficient intracortical inhibition in drug-naive children with attention-deficit hyperactivity disorder is enhanced by methylphenidate. Neurosci Lett. 2000;284:121-125. (Pubitemid 30193214)
22. Gilbert DL, Ridel KR, Sallee FR, et al. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology. 2006;31:442-449. (Pubitemid 43113408)
23. Moll GH, Heinrich H, Rothenberger A. Methylphenidate and intracortical excitability: opposite effects in healthy subjects and attentiondeficit hyperactivity disorder. Acta Psychiatr Scand. 2003;107:69-72. (Pubitemid 36092247)
24. Ilic TV, Korchounov A, Ziemann U. Methylphenidate facilitates and disinhibits the motor cortex in intact humans. Neuroreport. 2003;14:773-776. (Pubitemid 36570940)
25. Kirschner J, Moll GH, Fietzek UM, et al. Methylphenidate enhances both intracortical inhibition and facilitation in healthy adults. Pharmacopsychiatry. 2003;36:79-82. (Pubitemid 36609514)
26. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3:386-396. (Pubitemid 28442411)
27. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711. (Pubitemid 35335888)
28. Andrews GD, Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology. 2006;31:594-601. (Pubitemid 43276975)
29. Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997;131:71-78. (Pubitemid 27242857)
30. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52:456-463.
31. Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1410-1415. (Pubitemid 40798562)
32. Volkow ND, Wang GJ, Fowler JS, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry. 2004;161:1173-1180. (Pubitemid 38859165)
33. Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43:181-187. (Pubitemid 34087672)
34. Volkow ND, Fowler JS, Wang GJ, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol. 2002;12:557-566. (Pubitemid 35414373)
35. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-1331. (Pubitemid 28471187)
36. Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(suppl 1):S31-S43.
37. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132-2133. (Pubitemid 30008900)
38. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27:1518-1524.
39. Krause KH, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285:107-110. (Pubitemid 30227631)
40. Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57:1293-1300 (Pubitemid 40798548)
41. van Dyck CH, Quinlan DM, Cretella LM, et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2002;159:309-312. (Pubitemid 34126913)
42. Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse. 1998;29:93-104. (Pubitemid 28221788)
43. Krause J, Krause KH, Dresel SH, et al. ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. Dialogues Clin Neurosci. 2006;8:29-36.
44. 123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging. 2003;30:306-311. (Pubitemid 36686852)
45. Madras BK, Gracz LM, Meltzer PC, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain. Synapse. 1998;29:105-115. (Pubitemid 28221789)
46. Madras BK, Gracz LM, Fahey MA, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998;29:116-127. (Pubitemid 28221790)
47. Sonders MS, Zhu SJ, Zahniser NR, et al. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997;17:960-974. (Pubitemid 27043955)
48. Vles JS, Feron FJ, Hendriksen JG, et al. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics. 2003;34:77-80. (Pubitemid 36597126)
49. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387-395. (Pubitemid 44469379)
50. Krause J, la Fougere C, Krause KH, et al. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci. 2005;255:428-431. (Pubitemid 43029831)
51. Stoof JC, Kebabian JW. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 1984;35:2281-2296. (Pubitemid 15217782)
52. Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev. 1989;69:864-989. (Pubitemid 19184852)
53. Tepper J, Gariano R, Groves P. The neurophysiology of dopamine nerve terminal autoreceptors. In: Chiodo L, Freeman A, eds. Neurophysiology of Dopaminergic Systems: Current Status and Clinical Perspectives. Grosse Point, MI: Lakeshore; 1987.
54. Tepper JM, Sun BC, Martin LP, et al. Functional roles of dopamine d2 and d3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neurosci. 1997;17:2519-2530. (Pubitemid 27137418)
55. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
56. Rosa-Neto P, Lou HC, Cumming P, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage. 2005;25:868-876. (Pubitemid 40461725)
57. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64:932-940. (Pubitemid 47230617)
58. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naBve adults with ADHD. Neuroimage. 2007;34:1182-1190. (Pubitemid 46394475)
59. Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45:408-414. (Pubitemid 43675545)
60. Kroutil LA, Van Brunt DL, Herman-Stahl MA, et al. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84:135-143. (Pubitemid 44160579)
61. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1:2.
62. Kim CH, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A. 2006;103:19164-19169. (Pubitemid 350002844)
63. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784. (Pubitemid 38338092)
64. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.
65. Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004;43:1154-1158. (Pubitemid 39096873)
66. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60:1111-1120. (Pubitemid 44647216)
67. Kuczenski R, Segal DS. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther. 2001;296:876-883. (Pubitemid 32187360)
68. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397-1409. (Pubitemid 40798561)
69. Gobert A, Rivet JM, Audinot V, et al. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience. 1998;84:413-429. (Pubitemid 28122907)
70. Gresch PJ, Sved AF, Zigmond MJ, et al. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem. 1995;65:111-116.
71. Drouin C, Page M, Waterhouse B. Methylphenidate enhances noradrenergic transmission and suppressesmid-and long-latency sensory responses in the primary somatosensory cortex of awake rats. J Neurophysiol. 2006;96:622-632.
72. Ishimatsu M, Kidani Y, Tsuda A, et al. Effects of methylphenidate on the membrane potential and current in neurons of the rat locus coeruleus. J Neurophysiol. 2002;87:1206-1212. (Pubitemid 34670787)
73. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003;42:33-84. (Pubitemid 36369264)
74. Horner WE, Johnson DE, Schmidt AW, et al. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol. 2007;558:96-97. (Pubitemid 46328877)
75. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007;74:1212-1223. (Pubitemid 47417927)
76. Tzavara ET, Bymaster FP, Overshiner CD, et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry. 2006;11:187-195. (Pubitemid 43164620)
77. Easton N, Shah YB, Marshall FH, et al. Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast. Psychopharmacology (Berl). 2006;189(3):369-385. (Pubitemid 44773700)